Strategies to inhibit tumor associated integrin receptors: Rationale for dual and multi-antagonists

Journal of Medicinal Chemistry

Volumn 57, Issue 15, 2014, Pages 6301-6315

  Sheldrake, Helen M ^a   Patterson, Laurence H ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAIIBBETA3 INTEGRIN; ALPHAVBETA5 INTEGRIN; ALPHAVBETA6 INTEGRIN; ALPHAVBETA8 INTEGRIN; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; DISINTEGRIN; INTEGRIN RECEPTOR; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR; ANGIOGENESIS INHIBITOR; ARGINYL-GLYCYL-ASPARTIC ACID; INTEGRIN; OLIGOPEPTIDE;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; DRUG ANTAGONISM; DRUG TARGETING; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN STRUCTURE; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROTEIN CONFORMATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; HUMANS; INTEGRINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; OLIGOPEPTIDES; PROTEIN CONFORMATION;

EID: 84906091809     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5000547     Document Type: Review

References (153)

1. Humphries, J. D.; Byron, A.; Humphries, M. J. Integrin ligands at a glance J. Cell Sci. 2006, 119, 3901-3903
2. Xiao, T.; Takagi, J.; Coller, B. S.; Wang, J.-H.; Springer, T. A. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics Nature 2004, 432, 59-67
3. 1 integrin ectodomain: atomic details of the fibronectin receptor J. Cell Biol. 2012, 197, 131-140
4. 1 integrins J. Biol. Chem. 1994, 269, 20233-20238
5. Peishoff, C. E.; Ali, F. E.; Bean, J. W.; Calve, R.; D'Ambroeio, C. A.; Weston, D. S.; Hwang, S. M.; Kline, T. P.; Koeter, P. F.; Nichols, A.; Powers, D.; Romoff, T.; Samanen, J. M.; Stade, J.; Vasko, J. A.; Kopple, K. D. Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptides J. Med. Chem. 1992, 35, 3962-3969
6. 3 integrin ligands: pharmacophore refinement and implications for drug design J. Med. Chem. 2003, 46, 4393-4404
7. 1 integrin antagonists J. Med. Chem. 2005, 48, 4204-4207
8. 5: homology modeling and ligand binding J. Med. Chem. 2004, 47, 4166-4177
9. 6: conformational control through flanking amino acids J. Med. Chem. 2013, 56, 1509-1519
10. 6·uPAR interaction from structural modelling and docking J. Struct. Biol. 2014, 185, 327-335
11. Calderwood, D. A.; Tai, V.; Di Paolo, G.; De Camilli, P.; Ginsberg, M. H. Competition for talin results in trans-dominant inhibition of integrin activation J. Biol. Chem. 2004, 279, 28889-28895
12. Cox, D.; Brennan, M.; Moran, N. Integrins as therapeutic targets: lessons and opportunities Nat. Rev. Drug Discovery 2010, 9, 804-820
13. Goodman, S. L.; Picard, M. Integrins as therapeutic targets Trends Pharmacol. Sci. 2012, 33, 405-412
14. Nadrah, K.; Dolenc, M. S. Dual antagonists of integrins Curr. Med. Chem. 2005, 12, 1449-1466
15. Davenport, R. J.; Munday, J. R. Alpha4-integrin antagonism-an effective approach for the treatment of inflammatory diseases? Drug Discovery Today 2007, 12, 569-576
16. 3 J. Clin. Invest. 2005, 115, 3363-3369
17. Scarborough, R. M.; Gretler, D. D. Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents J. Med. Chem. 2000, 43, 3453-3473
18. Cohen, S. A.; Trikha, M.; Mascelli, M. A. Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications Pathol. Oncol. Res. 2000, 6, 163-174
19. Topol, E. J.; Califf, R. M.; Weisman, H. F.; Ellis, S. G.; Tcheng, J. E.; Worley, S.; Ivanhoe, R.; George, B. S.; Fintel, D.; Weston, M.; Sigmon, K.; Anderson, K. M.; Lee, K. L.; Willerson, J. T. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months Lancet 1994, 343, 881-886
20. The IMPACT-II Investigators. Randomised placebo-controlled trial of the effect of epifibatide on complications of percutaneous coronary intervention: IMPACT-II Lancet 1997, 349, 1422-1428
21. 3 potentiate bone resorption J. Biol. Chem. 1993, 268, 9901-9907
22. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 1994, 79, 1157-1164
23. 3-integrin transiently inhibits tumor growth and angiogenesis in mice Circ. Res. 2014, 114, 79-91
24. 3 expression on tumour associated vessels of human carcinomas Int. J. Cancer 1997, 71, 320-324
25. 3: a new prognostic indicator in breast cancer Clin. Cancer Res. 1998, 4, 2625-2634
26. 3 integrins in the development of cancer therapy Curr. Cancer Drug Targets 2009, 9, 519-540
27. 3 subunit with tumor progression Cancer Res. 1990, 50, 6757-6764
28. Malik, G.; Knowles, L. M.; Dhir, R.; Xu, S.; Yang, S.; Ruoslahti, E.; Pilch, J. Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion Cancer Res. 2010, 70, 4327-4334
29. 3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells Clin. Exp. Metastasis 2004, 21, 747-753
30. 3 modulates bone metastatic growth and tissue remodeling Oncogene 2007, 26, 6238-6243
31. 3 and fibronectin upregulate Slug in cancer cells to promote clot invasion and metastasis Cancer Res. 2013, 73, 6175-6184
32. Schneider, J. G.; Amend, S. H.; Weilbaecher, K. N. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions Bone 2011, 48, 54-65
33. 3 integrin is a therapeutic target for breast cancer bone metastases Cancer Res. 2007, 67, 5821-5830
34. 3 integrin promotes spontaneous metastasis of breast cancer to bone Breast Cancer Res. 2006, 8, R20
35. 3 expression confers on tumor cells a greater propensity to metastasize to bone FASEB J. 2002, 16, 1266-1268
36. 3 integrins in human melanoma growth and survival Int. J. Cancer 2002, 101, 156-167
37. 3 integrin in murine melanoma cells Clin. Exp. Metastasis 1998, 16, 437-445
38. Pontes-Júnior, J.; Reis, S. T.; Neves de Oliveira, L. C.; Sant'Anna, A. C.; Dall'Oglio, M. F.; Antunes, A. A.; Ribeiro-Filho, L.; Carvalho, P. A.; Cury, J.; Srougi, M.; Moreira Leite, K. R. Association between integrin expression and prognosis in localized prostatecancer Prostate 2010, 70, 1189-1195
39. 3 integrins in human melanoma cells upregulates bFGF expression and promotes their angiogenic phenotype Int. J. Cancer 2005, 116, 27-35
40. Oleksowicz, L.; Schwartz, Z. M. E.; Khorshidit, M.; Dutcher, J. P.; Puszkin, E. Characterisation of tumor-induced platelet aggregation: the role of immunoregulated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells Thromb. Res. 1995, 79, 261-274
41. Buergy, D.; Wenz, F.; Groden, C.; Brockmann, M. A. Tumor-platelet interaction in solid tumors Int. J. Cancer 2012, 130, 2747-2760
42. 3 mediates interaction of melanoma cells with platelets-a connection to hematogenous metastasis J. Biol. Chem. 2011, 287, 2168-2178
43. v integrins Int. J. Cancer 1997, 70, 201-207
44. Palumbo, J. S.; Talmage, K. E.; Massari, J. V.; La Jeunesse, C. M.; Flick, M. J.; Kombrinck, K. W.; Jirouskova, M.; Degen, J. L. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells Blood 2005, 105, 178-185
45. 3 integrins in MDA-MB-231 cell invasion and shear flow-induced cancer cell mechanotransduction Cancer Lett. 2014, 344, 62-73
46. 3 integrins in tumor growth, angiogenesis, and metastasis Cancer Res. 2002, 62, 2824-2833
47. 3 integrins Anticancer Res. 2009, 29, 131-137
48. 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment Blood 2012, 120, 2889-2898
49. Amirkhosravi, A.; Amaya, M.; Siddiqui, F.; Biggerstaff, J. P.; Meyer, T. V.; Francis, J. L. Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis Platelets 1999, 10, 285-292
50. 3 antagonists Clin. Exp. Metastasis 2004, 21, 553-561
51. 3 integrins during HeLa cells adhesion, migration, and invasion to monolayer endothelium under static and dynamic shear flow J. Biomed. Biotechnol. 2009, 2009, 829243
52. 3 J. Med. Chem. 2000, 43, 41-58
53. 5 integrins Bioorg. Med. Chem. Lett. 2004, 14, 5227-5232
54. Osterkamp, F.; Ziemer, B.; Koert, U.; Weisner, M.; Raddatz, P.; Goodman, S. L. Synthesis and biological evaluation of integrin antagonists containing trans-and cis-2,5-disubstituted THF rings Chem.-Eur. J. 2000, 6, 666-683
55. Barker, P. L.; Bullens, S.; Bunting, S.; Burdick, D. J.; Chan, K. S.; Deisher, T.; Eigenbrot, C.; Gadek, T. R.; Gantzos, R.; Lipari, M. T.; Muir, C. D.; Napier, M. A.; Pitti, R. M.; Padua, A.; Quan, C.; Stanley, M.; Struble, M.; Tom, J. Y. K.; Burnier, J. P. Cyclic RGD peptide analogues as antiplatelet antithrombotics J. Med. Chem. 1992, 35, 2040-2048
56. Matsuno, H.; Stassen, J. M.; Vermylen, J.; Deckmyn, H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation Circulation 1994, 90, 2203-2206
57. 3 on thrombosis and neointima after oversized porcine coronary angioplasty Circulation 2001, 103, 1135-1141
58. 3 integrin loop" regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway Oncogene 2005, 24, 761-779
59. v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors Anticancer Res. 1999, 19, 959-968
60. Davis, F. B.; Tang, H.-Y.; Shih, A.; Keating, T.; Lansing, L.; Hercbergs, A.; Fenstermaker, R. A.; Mousa, A.; Mousa, S. A.; Davis, P. J.; Lin, H.-Y. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells Cancer Res. 2006, 66, 7270-7275
61. 3 dual antagonistic activity Bioorg. Med. Chem. 2006, 14, 2089-2108
62. 3 selectivity by meta-oriented substitution Bioorg. Med. Chem. 2006, 14, 4158-4181
63. 3 dual antagonists Bioorg. Med. Chem. 2006, 14, 2109-2130
64. 3 dual activity and improved water solubility Bioorg. Med. Chem. 2006, 14, 2131-2150
65. 3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo J. Clin. Invest. 1997, 99, 2284-2292
66. v integrins Science 1995, 270, 1500-1502
67. 3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors Biol. Open 2012, 1, 329-340
68. Böger, C.; Kalthoff, H.; Goodman, S. L.; Behrens, H. M.; Röcken, C. Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression Virchows Arch. 2014, 464, 69-78
69. 5 integrin expression in glioma periphery Neurosurgery 2001, 49, 380-390
70. 5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide Cancer Res. 2000, 60, 712-721
71. De, S.; Chen, J.; Narizhneva, N. V.; Heston, W.; Brainard, J.; Sage, E. H.; Byzova, T. V. Molecular pathway for cancer metastasis to bone J. Biol. Chem. 2003, 278, 39044-39050
72. 5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways Oncogene 2013, 32, 3049-3058
73. 5 integrins J. Cell. Physiol. 1998, 176, 482-494
74. 5 Bioorg. Med. Chem. Lett. 2009, 19, 352-355
75. Trabocchi, A.; Menchi, G.; Cini, N.; Bianchini, F.; Raspanti, S.; Bottoncetti, A.; Pupi, A.; Calorini, L.; Guarna, A. Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis J. Med. Chem. 2010, 53, 7119-7128
76. 5 integrin receptor antagonist Cancer Res. 2001, 61, 2232-2238
77. Reynolds, A. R.; Hart, I. R.; Watson, A. R.; Welti, J. C.; Silva, R. G.; Robinson, S. D.; Violante, G.; Gourlaouen, M.; Salih, M.; Jones, M. C.; Jones, D. T.; Saunders, G.; Kostourou, V.; Perron-Sierra, F.; Norman, J. C.; Tucker, G. C.; Hodivala-Dilke, K. M. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors Nat. Med. 2009, 15, 392-400
78. v integrin antagonists Bioorg. Med. Chem. Lett. 2002, 12, 3291-3296
79. Burbridge, M. F.; Venot, V.; Casara, P. J.; Perron-Sierra, F.; Hickman, J. A.; Tucker, G. C. Decrease in survival threshold of quiescent colon carcinoma cells in the presence of a small molecule integrin antagonist Mol. Pharmacol. 2003, 63, 1281-1288
80. 5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells Blood 2006, 108, 3035-3044
81. Mas-Moruno, C.; Rechenmacher, F.; Kessler, H. Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation Anti-Cancer Agents Med. Chem. 2010, 10, 753-768
82. Aumailley, M.; Gurrath, M.; Müller, G.; Calvete, J.; Timpl, R.; Kessler, H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragments FEBS Lett. 1991, 291, 50-54
83. 3 integrin antagonists J. Med. Chem. 1999, 42, 3033-3040
84. 3 selectivity of the anti-angiogenic drug cilengitide by N-methylation Angew. Chem., Int. Ed. 2011, 50, 9496-9500
85. Scaringi, C.; Minniti, G.; Caporello, P.; Enrici, R. M. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results Anticancer Res. 2012, 32, 4213-4223
86. Marelli, U. K.; Rechenmacher, F.; Sobahi, T. R. A.; Mas-Moruno, C.; Kessler, H. Tumor targeting via integrin ligands Front. Oncol. 2013, 3, 222
87. Nabors, L. B.; Mikkelsen, T.; Hegi, M. E.; Ye, X.; Batchelor, T.; Lesser, G.; Peereboom, D.; Rosenfeld, M. R.; Olsen, J.; Brem, S.; Fisher, J. D.; Grossman, S. A.; New Approaches to Brain Tumor Therapy Central Nervous System Consortium. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306) Cancer 2012, 118, 5601-5607
88. Vermorken, J. B.; Guigay, J.; Mesia, R.; Trigo, J. M.; Keilholz, U.; Kerber, A.; Bethe, U.; Picard, M.; Brummendorf, T. H. Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part Br. J. Cancer 2011, 104, 1691-1696
89. 18F-FDG PET and gene expression analysis J. Cancer Res. Clin. Oncol. 2013, 139, 573-583
90. Bretschi, M.; Merz, M.; Komljenovic, D.; Berger, M. R.; Semmler, W.; Bauerle, T. Cilengitide inhibits metastatic bone colonization in a nude rat model Oncol. Rep. 2011, 26, 843-851
91. Martin, S.; Janouskova, H.; Dontenwill, M. Integrins and p53 pathways in glioblastoma resistance to temozolomide Front. Oncol. 2012, 2, 157
92. 1, the fibronectin receptor, as a pertinent therapeutic target in solid tumors Cancers 2013, 5, 27-47
93. Romanov, V. I.; Goligorsky, M. S. RGD-recognizing integrins mediate interactions of human prostate carcinoma cells with endothelial cells in vitro Prostate 1999, 39, 108-118
94. 3 integrins in relation to adhesion and spreading dynamics of prostate cancer cells interacting with fibronectin under in vitro conditions Cell Biol. Int. 2012, 36, 883-892
95. 1-mediated cell migration toward fibronectin J. Biol. Chem. 1997, 272, 29380-29389
96. 1 and protein kinase A J. Biol. Chem. 2000, 275, 33920-33928
97. 3 integrin switching that drives breast cancer metastasis by TGF-β Mol. Biol. Cell 2013, 24, 3449-3459
98. 3 integrin recycling and tumor cell invasive migration through its substrate rabaptin-5 Dev. Cell 2012, 23, 560-572
99. v integrins cooperate in remodeling of the vasculature during development Development 2010, 137, 2439-2449
100. Wan, A. M.; Chandler, E. M.; Madhavan, M.; Infanger, D. W.; Ober, C. K.; Gourdon, D.; Malliaras, G. G.; Fischbach, C. Fibronectin conformation regulates the proangiogenic capability of tumor-associated adipogenic stromal cells Biochim. Biophys. Acta 2013, 1830, 4314-4320
101. 1 integrins on capillary tube formation in a human fibrinous matrix Angiogenesis 2009, 12, 275-285
102. 1 antagonists J. Med. Chem. 2007, 50, 3786-3794
103. 1 integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds Bioorg. Med. Chem. 2007, 15, 7380-7390
104. 1-integrin-mediated adhesion by dehydro-β-amino acids containing peptidomimetics Eur. J. Med. Chem. 2013, 66, 258-268
105. 3 integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics J. Med. Chem. 2010, 53, 106-118
106. Smallheer, J. M.; Weigelt, C. A.; Woerner, F. J.; Wells, J. S.; Daneker, W. F.; Mousa, S. A.; Wexler, R. R.; Jadhav, P. K. Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds Bioorg. Med. Chem. Lett. 2004, 14, 383-387
107. 3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model FASEB J. 2008, 22, 4179-4189
108. 6 in cancer Curr. Drug Targets 2009, 10, 645-652
109. 3 integrins J. Med. Chem. 2002, 45, 1045-1051
110. 3 as a negative prognostic factor J. Neuropathol. Exp. Neurol. 2013, 72, 194-210
111. v-Integrin isoform expression in primary human tumors and brain metastases Int. J. Cancer 2013, 133, 2362-2371
112. 8, fibronectin and fibrinogen in human brain metastases and their corresponding primary tumors Int. J. Clin. Exp. Pathol. 2013, 6, 2719-2732
113. Bisanz, K.; Yu, J.; Edlund, M.; Spohn, B.; Hung, M.-C.; Chung, L. W. K.; Hsieh, C.-L. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model Mol. Ther. 2005, 12, 634-643
114. v expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer Am. J. Pathol. 2011, 179, 2559-2568
115. v integrins, has antitumor and antiangiogenic activiy in vivo Int. J. Cancer 2004, 110, 326-335
116. V-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model J Neuro-Oncol. 2012, 110, 27-36
117. v integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells Clin. Exp. Metastasis 2008, 25, 139-148
118. v integrin monoclonal antibody, despite widespread tissue binding Clin. Cancer Res. 2005, 11, 6959-6965
119. Mullamitha, S. A.; Ton, N. C.; Parker, G. J.; Jackson, A.; Julyan, P. J.; Roberts, C.; Buonaccorsi, G. A.; Watson, Y.; Davies, K.; Cheung, S.; Hope, L.; Valle, J. W.; Radford, J. A.; Lawrance, J.; Saunders, M. P.; Munteanu, M. C.; Nakada, M. T.; Nemeth, J. A.; Davis, H. M.; Jiao, Q.; Prabhakar, U.; Lang, Z.;
120. O'Day, S. J.; Pavlick, A. C.; Albertini, M. R.; Hamid, O.; Schalch, H.; Lang, Z.; Ling, J.; Mata, M.; Reddy, M.; Foster, B. Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma Invest. New Drugs 2012, 30, 1074-1081
121. v-integrin mAb, alone and with dacarbazine in stage IV melanoma Br. J. Cancer 2011, 105, 346-352
122. Chu, F. M.; Picus, J.; Fracasso, P. M.; Dreicer, R.; Lang, Z.; Foster, B. A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer Invest. New Drugs 2011, 29, 674-679
123. v integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer Ann. Oncol. 2013, 24, 329-336
124. v integrins Int. J. Cancer 2000, 87, 716-723
125. v- integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses. Invest. New Drugs [Online early access]. DOI: 10.1007/s10637-013-038-5. Published Online: November 19, 2013.
126. v integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy. Eur. Urol. [Online early access]. DOI: 10.1016/j.eururo.2013.05.051. Published Online: June 6, 2013.
127. Scarborough, R. M. Development of eptifibatide Am. Heart J. 1999, 138, 1093-1104
128. Calvete, J. J. The continuing saga of snake venom disintegrins Toxicon 2013, 62, 40-49
129. 1 integrins Biochemistry 2002, 41, 2014-2021
130. Sánchez, E. E.; Rodríguez-Acosta, A.; Palomar, R.; Lucena, S. E.; Bashir, S.; Soto, J. G.; Pérez, J. C. Colombistatin: a disintegrin isolated from the venom of the South American snake (Bothrops colombiensis) that effectively inhibits platelet aggregation and SK-Mel-28 cell adhesion Arch. Toxicol. 2009, 83, 271-279
131. Lucena, S. E.; Jia, Y.; Soto, J. G.; Parral, J.; Cantu, E.; Brannon, J.; Lardner, K.; Ramos, C. J.; Seoane, A. I.; Sánchez, E. E. Anti-invasive and anti-adhesive activities of a recombinant disintegrin, r-viridistatin 2, derived from the Prairie rattlesnake (Crotalus viridis viridis) Toxicon 2012, 60, 31-39
132. Carey, C. M.; Bueno, R.; Gutierrez, D. A.; Petro, C.; Lucena, S. E.; Sanchez, E. E.; Soto, J. G. Recombinant rubistatin (r-Rub), an MVD disintegrin, inhibits cell migration and proliferation, and is a strong apoptotic inducer of the human melanoma cell line SK-Mel-28 Toxicon 2012, 59, 241-248
133. 5-dependent functions in melanoma cells by an ECD-disintegrin acurhagin-C Matrix Biol. 2013, 32, 152-159
134. Kang, I.-C.; Kim, D.-S.; Jang, Y.; Chung, K.-H. Suppressive mechanism of salmosin, a novel disintegrin in B16 melanoma cell metastasis Biochem. Biophys. Res. Commun. 2000, 275, 169-173
135. 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis Cancer Res. 1994, 54, 4993-4998
136. Minea, R. O.; Helchowski, C. M.; Zidovetzki, S. J.; Costa, F. K.; Swenson, S. D.; Markland, F. S. J. Vicrostatin-an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities PLoS One 2010, 5, e10929
137. Minea, R.; Swenson, S.; Costa, F.; Chen, T. C.; Markland, F. S. Development of a novel recombinant disintegrin, contortrostatin, as an effective anti-tumor and anti-angiogenic agent Pathophysiol. Haemostasis Thromb. 2005, 34, 177-183
138. Swenson, S.; Costa, F.; Minea, R.; Sherwin, R. P.; Ernst, W.; Fujii, G.; Yang, D.; Markland, F. S., Jr. Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression Mol. Cancer Ther. 2004, 3, 499-511
139. v-mediated proliferation of SK-Mel-2 human melanoma cells J. Pharm. Pharmacol. 2003, 55, 1577-1582
140. Lin, E.; Wang, Q.; Swenson, S.; Jadvar, H.; Groshen, S.; Ye, W.; Markland, F. S.; Pinski, J. The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo Prostate 2010, 70, 1359-1370
141. Morjen, M.; Kallech-ziri, O.; Bazaa, A.; Othman, H.; Mabrouk, K.; Zouari-kessentini, R.; Sanz, L.; Calvete, J. J.; Srairi-Abid, N.; Ayeb, El; Luis, J.; Marrakchi, N. PIVL, a new serine protease inhibitor from Macrovipera lebetina transmediterranea venom, impairs motility of human glioblastoma cells Matrix Biol. 2013, 32, 52-62
142. Hailey, S.; Adams, E.; Penn, R.; Wong, A.; McLane, M. A. Effect of the disintegrin eristostatin on melanoma-natural killer cell interactions Toxicon 2013, 61, 83-93
143. 3 receptor antagonists Bioorg. Med. Chem. Lett. 2006, 16, 839-844
144. Shannon, K. E.; Keene, J. L.; Settle, S. L.; Duffin, T. D.; Nickols, M. A.; Westlin, M.; Schroeter, S.; Ruminski, P. G.; Griggs, D. W. Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247 Clin. Exp. Metastasis 2004, 21, 129-138
145. 1 induces apoptosis of angiogenic endothelial cells on type I collagen Vasc. Pharmacol. 2003, 40, 77-89
146. 3 expression Cell. Oncol. 2012, 35, 19-28
147. v integrin identifies a core molecular pathway that regulates fibrosis in several organs Nat. Med. 2013, 19, 1617-1624
148. 3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice Cancer Res. 2003, 63, 2079-2087
149. 3 integrin suppresses MDA-MB-435 skeletal metastasis Clin. Exp. Metastasis 2004, 21, 119-128
150. Heckmann, B.; Lefrancois, J.-M.; Pyrimidines derivatives as antagonists of the vitronectine receptors. European Patent EP2368891A1, September 28, 2011.
151. v integrins, a potential marker for tumor-initiating cells, in prostate cancer and bone stroma inhibits bone metastasis formation Bone 2010, 47, S320
152. v-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer Neoplasia 2011, 13, 516-525
153. Clinicaltrials.gov. www.clinicaltrials.gov (accessed Nov 27, 2013).